Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 236,000,838 papers from all fields of science
Search
Sign In
Create Free Account
AZD2014
Known as:
AZD 2014
, AZD-2014
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Morpholines
Vistusertib
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
PD10-02 THE MTORC1/2 DUAL INHIBITOR AZD2014 WITH POTENT ANTITUMOR ACTIVITY IN DOCETAXEL SENSITIVE/RESISTANT PROSTATE CANCER IN VITRO
Senmao Li
,
Shuai Hu
,
Wei Yu
,
Jie Jin
2020
Corpus ID: 218934052
INTRODUCTION AND OBJECTIVE:The mammalian target of rapamycin (mTOR) is a vital effect factor in regulating cell growth, survival…
Expand
2019
2019
Targeting MTOR and metabolic pathways for anti-tumour therapy in a TSC2+/- mouse model
Ashley T. Jones
2019
Corpus ID: 204045585
Tuberous sclerosis (TSC) is a genetic tumour syndrome characterised by the formation of tumours in multiple organs, including the…
Expand
Review
2017
Review
2017
Abstract PD1-08: High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: First feasibility and molecular results of the randomized phase II…
A. Gonçalves
,
T. Bachelot
,
+17 authors
F. André
2017
Corpus ID: 78779716
Background A genomic-driven therapeutic strategy in metastatic breast cancer (MBC) was recently demonstrated as feasible in the…
Expand
2017
2017
A Phase II Study to Determine the Safety and Efficacy of the Dual m-TORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination with Rituximab in Relapsed/Refractory Diffuse Large…
K. Linton
2017
Corpus ID: 86398694
2017
2017
Phase 2 Study of AZD2014, a Dual mTORC1/mTORC1 Inhibitor,for NF2 Patients with Progressive or Symptomatic Meningiomas
S. Plotkin
2017
Corpus ID: 80590727
2016
2016
Abstract OT1-03-12: MANTA: A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or…
P. Schmid
,
M. Zaiss
,
+23 authors
J. C. Castán
2016
Corpus ID: 77260028
Background: Resistance to endocrine therapy remains a major clinical challenge with aberrant PI3K/ mTOR pathway activation being…
Expand
2016
2016
TAX-TORC: An investigator initiated phase I study combining the dual mTORC1/2 inhibitor AZD2014 in combination with weekly paclitaxel in high-grade serous ovarian cancer
U. Banerji
,
B. Basu
,
+11 authors
J. Bono
2016
Corpus ID: 57838610
2015
2015
Preclinical Evaluation of Dual mTOR Inhibitor, AZD2014, in Prostate Cancer
C. Sandi
,
A. Ramos-Montoya
,
+10 authors
S. Pacey
2015
Corpus ID: 80183076
This is the accepted manuscript. The final version is available at http://mct.aacrjournals.org/content/14/12_Supplement_2/A123…
Expand
2012
2012
Abstract PD01-01: Overcoming endocrine therapy resistance related to PTEN loss by strategic combinations with mTOR, AKT, or MEK inhibitors
X. Fu
,
Vijetha Kumar
,
+13 authors
R. Schiff
2012
Corpus ID: 70865177
Background: Hyperactive PI3K signaling is associated with a more aggressive subtype of estrogen receptor (ER) positive breast…
Expand